CAS No. :	254750-02-2
Formula :	C₂₆H₂₇F₄N₃O₇
M.W :	569.50
SMILES Code :	O=C(O)C[C@H](NC([C@@H](NC(C(NC1=CC=CC=C1C(C)(C)C)=O)=O)C)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O
Synonyms :	IDN-6556; PF 03491390
MDL No. :	MFCD11840420
InChI Key :	SCVHJVCATBPIHN-SJCJKPOMSA-N
Pubchem ID :	12000240

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H302-H319-H372-H410
Precautionary Statements:	P260-P264-P273-P301+P312-P305+P351+P338-P314
Class:	9
UN#:	3077
Packing Group:	Ⅲ

Molm-13 cells	1 µM	10 h	To investigate the effect of Emricasan on necroptosis in Molm-13 cells, results showed that Beclin 1 depletion enhanced Smac mimetic- and caspase inhibitor-induced necroptosis.	Cell Death Differ. 2020 Nov;27(11):3065-3081.
Molm13 cells	1 μM		To investigate the effect of Emricasan in combination with birinapant on necroptosis in Molm13 cells, results showed that MYC depletion sensitized cells to necroptosis	Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19982-19993.
hepatocytes	50 μM	24 h	Emricasan directly improved the phenotype of hepatocytes and ameliorated nonparenchymal cells through a paracrine mechanism	Hepatol Commun. 2019 Apr 22;3(7):987-1000.
N/TERT cells	5 µM	3 h	Emricasan was used to inhibit cell death, including caspase-1-driven pyroptosis, to study the effects of nigericin on translation.	Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2309579121.
Primary keratinocytes	5 µM	3 h	Emricasan was used to inhibit cell death, including caspase-1-driven pyroptosis, to study the effects of nigericin on translation.	Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2309579121.
HT1080 cells	5 µM	20 to 40 h	To detect whether dexamethasone-induced apoptosis can be reversed by the caspase inhibitor emricasan. The results show that emricasan can reverse dexamethasone-induced apoptosis	Sci Adv. 2022 Feb 4;8(5):eabl8920.
non-ciliated kidney cells	10 µM	16 h	To study the effect of Emricasan on cell death, results showed that Emricasan significantly enhanced necroptotic death in non-ciliated cells.	Cell Death Discov. 2022 Dec 2;8(1):477.
ciliated kidney cells	10 µM	16 h	To study the effect of Emricasan on cell death, results showed that Emricasan had no significant effect on the viability of ciliated cells.	Cell Death Discov. 2022 Dec 2;8(1):477.
RAW-Lucia ISG cells	1 µM	24 h	To evaluate the effect of Emricasan on the production of type I IFNs in RAW-Lucia ISG cells, the results showed that Emricasan alone did not effectively induce the production of type I IFNs, but significantly enhanced the production of type I IFNs when combined with other drugs.	J Immunother Cancer. 2023 Dec 6;11(12):e007625.
MC38 cells	10 µM	24 h	To evaluate the effect of Emricasan combined with luminespib on the expression of IFN-β in MC38 cells, the results showed that the combination significantly enhanced the expression of IFN-β.	J Immunother Cancer. 2023 Dec 6;11(12):e007625.
HT29 cells	10 µM	24 h	To evaluate the effect of Emricasan combined with luminespib on the expression of IFN-β mRNA in HT29 cells, the results showed that the combination significantly enhanced the expression of IFN-β mRNA.	J Immunother Cancer. 2023 Dec 6;11(12):e007625.

Balb/c nude mice	Subcutaneous tumor xenograft model	Intraperitoneal injection	1 mg/kg	Every two days for two weeks	To investigate the effect of Emricasan on necroptosis in Beclin 1-depleted Molm-13 cells in vivo, results showed that Beclin 1 depletion significantly enhanced the inhibitory effect of birinapant and emricasan combination therapy on tumor growth.	Cell Death Differ. 2020 Nov;27(11):3065-3081.
Mice	Humanized mouse model	Intraperitoneal injection	10 mg/kg	Daily, until day 10 post-infection	Inhibition of necroptosis did not affect the progression of tuberculosis	Cell Death Differ. 2018 May;25(5):951-965.
Nude mice	Subcutaneous tumor xenograft model	Intraperitoneal injection	1 mg/kg	Every 2 days for 2 weeks	To investigate the effect of Emricasan in combination with birinapant on MYC-depleted Molm13 cell xenograft tumors, results showed that MYC depletion significantly inhibited tumor growth	Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19982-19993.
Rats	Cirrhosis model	Oral	10 mg/kg	Once daily for 7 days	Emricasan significantly reduced portal pressure, improved liver function and fibrosis, and decreased hepatic cell death	Hepatol Commun. 2019 Apr 22;3(7):987-1000.
C57BL/6J mice	MC38 tumor model	Intratumoral injection	10 mg/kg	Daily for 7 days	To evaluate the effect of Emricasan combined with luminespib on tumor growth inhibition in the MC38 tumor model, the results showed that the combination significantly inhibited tumor growth and enhanced anti-tumor immune responses.	J Immunother Cancer. 2023 Dec 6;11(12):e007625.

NCT00088140	Hepatitis C, Chronic	Phase 2	Completed	-	United States, Arizona ... More >> Mayo Clinic Hospital Phoenix, Arizona, United States, 85054 United States, California Scripps Clinic La Jolla, California, United States, 92067 California Pacific Medical Center San Francisco, California, United States, 94115 University of California, San Francisco San Francisco, California, United States, 94143 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Indiana Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 United States, Massachusetts Beth Israel Deaconness Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Minnesota The Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Mt. Sinai School of Medicine New York City, New York, United States, 10029 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 Duke University Medical Center Durham, North Carolina, United States, 27715 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 Metrohealth Medical Center Cleveland, Ohio, United States, 44109 United States, Virginia Medical College of Virginia Richmond, Virginia, United States, 23298 Less <<
NCT00080236	Liver Transplantation ... More >> Hepatitis Cholestasis Carcinoma, Hepatocellular Less <<	Phase 2	Completed	-	United States, Arizona ... More >> Mayo Clinic Scottsdale Phoenix, Arizona, United States, 85054 United States, California University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94143 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 United States, Louisiana Tulane University Hospital and Clinic New Orleans, Louisiana, United States, 70112 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, New York Mount Sinai School of Medicine New York City, New York, United States, 10029 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 United States, Texas Baylor Regional Transplant Institute, Baylor University Medical Center Dallas, Texas, United States, 75246 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 Germany Oberarzt der Klinik für Allgemein-, Viszeral- und Transplantationschirurgie Charité-Virchow Berlin, Germany, D-13353 Klinik für Viszeral- und Transplantationschirurgie Medizinische Hochschule Hannover Hannover, Germany, D-30623 Abteilung für Transplantationschirurgie Johannes Gutenberg-Universität Mainz Mainz, Germany, 55101 Less <<
NCT01937130	Acute on Chronic Hepatic Failu... More >>re Acute Liver Failure Liver Cirrhosis Acute Alcoholic Hepatitis Less <<	Phase 2	Terminated(Data needs met)	-	United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Scripps Clinic La Jolla, California, United States, 92037 VA San Diego Healthcare System San Diego, California, United States, 92161 Sutter Pacific Medical Foundation San Francisco, California, United States, 94115 United States, District of Columbia Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Kentucky Univerisity of Louisville Liver Research Center Louisville, Kentucky, United States, 40202 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 United States, Washington University of Washington Harborview Medical Center Seattle, Washington, United States, 98104 United Kingdom Singleton Hospital Swansea, Wales, United Kingdom, SA2 8QA Basildon and Thurrock University Hospital Basildon, United Kingdom, SS16 5NL Blackpool Victoria Hospital Blackpool, United Kingdom, FY3 8NR Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Ninewells Hospital Dundee, United Kingdom, DD1 9SY Glasgow Royal Infirmary Glasgow, United Kingdom Leicester Royal Infirmary Leicester, United Kingdom, LE1 5WW Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP University College London, Royal Free Hospital London, United Kingdom, NW3 2PF Royal London Hospital London, United Kingdom Central Manchester University Hospitals NHS Trust Manchester, United Kingdom, M13 9WL Freeman Hospital Newcastle upon tyne, United Kingdom, NE7 7DN Nottingham University Hospitals NHS Trust Nottingham, United Kingdom, NG7 2UH Derriford Hospital Plymouth, United Kingdom Queen Alexandra Hospital Portsmouth, United Kingdom, PO6 3LY Less <<
NCT01937130	-		Terminated(Data needs met)	-	-
NCT02121860	Hepatic Impairment\|Liver Disea... More >>ses\|Digestive System Diseases Less <<	PHASE1	COMPLETED	2025-07-14	Avail Clinical Research, DeLan... More >>d, Florida, 32720, United States\|University of Miami, Miami, Florida, 33136, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT02121860	Hepatic Impairment\|Liver Disea... More >>ses\|Digestive System Diseases Less <<	PHASE1	COMPLETED	2025-07-14	Avail Clinical Research, DeLan... More >>d, Florida, 32720, United States\|University of Miami, Miami, Florida, 33136, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT02039817	Renal Impairment\|Renal Insuffi... More >>ciency\|Kidney Disease\|Kidney Diseases Less <<	PHASE1	COMPLETED	2025-04-14	Avail Clinical Research, DeLan... More >>d, Florida, 32720, United States\|University of Miami, Miami, Florida, 33136, United States Less <<
NCT02138253	Liver Fibrosis ... More >> Hepatic Fibrosis Liver Cirrhosis Hepatic Cirrhosis Less <<	Phase 2	Completed	-	-
NCT02230670	Liver Cirrhosis ... More >> Hepatic Cirrhosis Less <<	Phase 2	Completed	-	-
NCT01912404	Alcoholic Hepatitis	Phase 2	Terminated(Due to concern for ... More >>high systemic drug levels that could exceed levels in toxicology studies.) Less <<	-	United States, Indiana ... More >> Indiana University Indianapolis, Indiana, United States, 46202 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<
NCT02230670	-		Completed	-	-
NCT02039817	Renal Impairment\|Renal Insuffi... More >>ciency\|Kidney Disease\|Kidney Diseases Less <<	PHASE1	COMPLETED	2025-04-14	Avail Clinical Research, DeLan... More >>d, Florida, 32720, United States\|University of Miami, Miami, Florida, 33136, United States Less <<
NCT01653899	Diabetes	PHASE1\|PHASE2	COMPLETED	2025-06-16	University of Alberta, Edmonto... More >>n, Alberta, Canada Less <<
NCT02077374	Nonalcoholic Steatohepatitis ... More >> Non-alcoholic Fatty Liver Disease Less <<	Phase 2	Completed	-	United States, Florida ... More >> University of Miami Miami, Florida, United States, 33136 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Missouri Kansas City Research Institute Kansas City, Missouri, United States, 64131 United States, Virginia Mary Immaculate Hospital Newport News, Virginia, United States, 23602 Bon Secours St. Mary's Hospital Richmond, Virginia, United States, 23226 Less <<
NCT02077374	-		Completed	-	-
NCT02960204	Cirrhosis Por... More >>tal Hypertension Non-alcoholic Steatohepatitis Less <<	Phase 2	Active, not recruiting	April 2019	-
NCT03479125	-		Enrolling by invitation	May 31, 2022	United States, California ... More >> Inland Empire Liver Foundation Rialto, California, United States, 92377 United States, Oklahoma Options Health Research, LLC Tulsa, Oklahoma, United States, 74104 United States, Tennessee Gastro One Germantown, Tennessee, United States, 38138 Less <<
NCT01912404	-		Terminated(Due to concern for ... More >>high systemic drug levels that could exceed levels in toxicology studies.) Less <<	-	-
NCT02230683	Liver Cirrhosis\|Hepatic Cirrho... More >>sis\|Portal Hypertension Less <<	PHASE2	COMPLETED	2025-06-15	VA Connecticut Healthcare Syst... More >>em, West Haven, Connecticut, 06516, United States\|Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States\|University of Miami, Miami, Florida, 33136, United States\|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States\|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States\|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States\|North Shore University Hospital, Manhasset, New York, 11030, United States\|New York University Lagone Medical Center, NYC, New York, 10016, United States\|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States\|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States\|St. Luke's Health Baylor College of Medicine, Houston, Texas, 77030, United States\|University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States\|University of Utah Hospital, Salt Lake City, Utah, 84132, United States\|Bon Secours Mary Immaculate Hospital, Newport News, Virginia, 23602, United States\|Bon Secours St. Mary's Hospital, Richmond, Virginia, 23226, United States\|McGuire DVAMC, Richmond, Virginia, 23249, United States Less <<
NCT02686762	Non-alcoholic Steatohepatitis ... More >> Fibrosis Liver Diseases Less <<	Phase 2	Active, not recruiting	January 2019	-
NCT03205345	Decompensated Cirrhosis	Phase 2	Recruiting	August 2019	-
NCT02230683	Liver Cirrhosis\|Hepatic Cirrho... More >>sis\|Portal Hypertension Less <<	PHASE2	COMPLETED	2025-06-15	VA Connecticut Healthcare Syst... More >>em, West Haven, Connecticut, 06516, United States\|Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States\|University of Miami, Miami, Florida, 33136, United States\|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States\|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States\|Rutgers New Jersey Medical School, Newark, New Jersey, 07103, United States\|North Shore University Hospital, Manhasset, New York, 11030, United States\|New York University Lagone Medical Center, NYC, New York, 10016, United States\|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States\|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States\|St. Luke's Health Baylor College of Medicine, Houston, Texas, 77030, United States\|University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States\|University of Utah Hospital, Salt Lake City, Utah, 84132, United States\|Bon Secours Mary Immaculate Hospital, Newport News, Virginia, 23602, United States\|Bon Secours St. Mary's Hospital, Richmond, Virginia, 23226, United States\|McGuire DVAMC, Richmond, Virginia, 23249, United States Less <<

{[proInfo.proName]}

CAS No.: 254750-02-2

{[proInfo.proName]}

CAS No.: 254750-02-2

Alternative Products

Product Details of Emricasan

Safety of Emricasan

Related Pathways of Emricasan

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed